I understand your point clearly and its clear to me:
- small caps like this are easy targets in current market via creating seller ceiling with larger lots
- the p values are NOT the issue given the design of the trial was NEVER powered to achieve it. The effect size of cartilage regrowth shows DMOAD and surely will be ensure to get China and BP over the line given the upside to them. The FDA approach to include it in existing trials is a TBA but not a reason to short.
- you only execute such a trade when the asymmetrical risk reward is in your favour.
Ann: Trading Halt, page-105
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 337 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |